Navigation Links
Amylin Pharmaceuticals to Present at Research & Development Day
Date:11/21/2007

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at its Research & Development (R&D) Day on Wednesday, November 28, 2007 at 10:00 a.m. ET at the Grand Hyatt Hotel in New York.

"Amylin is focused on bringing innovative medicines with life-changing therapeutic potential to patients through our sustainable approach to the discovery and development of drugs," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. "At this year's R&D Day, we look forward to presenting an update on our opportunities to build near-term value with our marketed products, discussing our recent exciting clinical results from the once-weekly exenatide program and the pramlintide/leptin program, and providing insights into our research strategy."

The agenda for this year's R&D Day includes presentations by the following officers of Amylin Pharmaceuticals:

-- Introduction

Daniel M. Bradbury

President and Chief Executive Officer

-- Diabetes Programs

Orville Kolterman, MD

Senior Vice President of Clinical and Regulatory Affairs

-- Obesity Programs

Alain Baron, MD

Senior Vice President of Research

-- Discovery Research

Michael Hanley, PhD

Vice President of Discovery Research

A question and answer session will follow the presentations.

The presentation will be webcast live through Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to http://www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,800 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 20, 2017 , ... Pot. Reefer. Grass. Mary Jane. ... it, and share its attributes like never before. More than a map, new social ... enthusiasts to stores, strains, products – and for the first time – each other. ...
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... ... if it's been longer than six months since you've seen a dentist, it's ... twice per year and getting x-rays once per year. , Dental checkups are ...
(Date:5/19/2017)... Vermont (PRWEB) , ... May 19, 2017 , ... Springfield, ... its company blog. Titled " Ten Good Reasons To Hire An Experienced Personal Injury ... to make following an accident or injury. As the article says. if someone is ...
(Date:5/19/2017)... , ... May 19, 2017 , ... As a groundbreaking ... knows the importance of prostate cancer screenings. Early detection of the disease, he says, ... robotic surgery at Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Kim Ross supports Stroke Awareness Month by ... the link between this condition and serious systemic health conditions including heart disease and ... in Annapolis, MD, and seeking treatment with Dr. Ross immediately may prevent bacteria ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... quarter ended April 1, 2017 .   GAAP diluted ... to the prior year period as the sale of ... while non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue ... currency terms.  Excluding the effects of blood screening and ...
(Date:5/10/2017)... CSSi, the global leader in patient recruitment, ... is proud to announce the launch of its newly ... both enriched content and a customized layout that provides ... already well-established position as the top global patient recruitment ... months of hard work, we are delighted to officially ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
Breaking Medicine Technology: